SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001214659-19-004305
Filing Date
2019-06-24
Accepted
2019-06-24 16:39:24
Documents
1
Group Members
ANDREW J. M. SPOKESDAVID T. KIMFARALLON CAPITAL (AM) INVESTORS, L.P.FARALLON CAPITAL F5 MASTER I, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.FARALLON CA

Document Format Files

Seq Description Document Type Size
1 r624190sc13g.htm SC 13G 309868
  Complete submission text file 0001214659-19-004305.txt   312502
Mailing Address ONE WORLD TRADE CENTER 47TH FLOOR NEW YORK NY 10007
Business Address ONE WORLD TRADE CENTER 47TH FLOOR NEW YORK NY 10007 646-975-2500
PROGENICS PHARMACEUTICALS INC (Subject) CIK: 0000835887 (see all company filings)

IRS No.: 133379479 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-52343 | Film No.: 19915840
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address ONE MARITIME PLAZA SUITE 2100 SAN FRANCISCO CA 94111
Business Address ONE MARITIME PLAZA SUITE 2100 SAN FRANCISCO CA 94111 (415)421-2132
FARALLON CAPITAL MANAGEMENT LLC (Filed by) CIK: 0000909661 (see all company filings)

IRS No.: 943240279 | State of Incorp.: DE
Type: SC 13G